Pharmaceuticals

Newly independent Ennature Biopharma is betting on validated science for its botanicals, aiming to lead the booming women's health market with transparency.

Digital therapeutics 1.0 crashed and burned. By fusing software directly with standard prescriptions, a new hybrid model is rewriting the pharma playbook.

A landmark partnership will use a twice-yearly injection and a powerful regional fund to combat rising HIV rates across Latin America and the Caribbean.

A late-stage biotech is betting on a novel idea: what if we could repair eye damage at a structural level? Stuart Therapeutics' PolyCol™ platform aims to do just that.

Promising trial data for a novel drug targets a stubborn lung cancer mutation, signaling a major strategic advance for BlossomHill Therapeutics and the oncology field.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?

A small biotech assembles top experts to guide a promising, Sanofi-licensed drug through trials, betting it can solve a stubborn cardiovascular challenge.

With impressive Phase 2 data, Revelyx Bio's ready-to-use recombinant toxin YY003 signals a major technological and practical shift for the aesthetics industry.

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

Quebec-based Devonian Health Group plans a NYSE American debut, seeking U.S. capital to advance its promising pipeline of autoimmune disease treatments.

A Michigan biotech just patented a way to turn yeast into tiny drug factories inside you. It’s a blueprint for a future without injections or cold chains.

A new study reveals an mRNA flu vaccine sustains immune responses for months, a breakthrough that could lead to multi-season protection and end the annual flu shot.

XORTX starts manufacturing its gout drug XORLO™, a pivotal move toward FDA approval. But can it navigate a competitive market and its own financial hurdles?

CSL Seqirus's new flu shot combines three proven technologies. A landmark Lancet study validates its strategic R&D investment in the senior healthcare market.

A French biotech takes a critical step to industrialize a promising therapy for LCAT deficiency, navigating the high-stakes regulatory world of biologics.

A €30M investment from the EIB and HERA is backing Ethris's novel mRNA therapeutic. Delivered via nasal spray, it aims to treat chronic respiratory ills and act as a broad-spectrum antiviral.

With Phase 3 data imminent and a new Nasdaq ticker, Helus Pharma is using a key investor conference to frame its novel therapies as the next frontier.

Takeda's new rare blood cancer drug, MIMRYLO, partners with Onco360 in a strategic 'ultra-narrow' launch, signaling a major shift in patient care.

As Cardiol Therapeutics prepares for a key investor conference, it's not just a presentation; it's a test of its strategy to build a durable franchise in heart disease.

Cure Alzheimer's Fund is recruiting top drug developers, including the mind behind Kisunla™, to steer its research—all while refusing industry money.